论文部分内容阅读
为评估国产重组人粒细胞集落刺激因子在动员外周造血干细胞的效果,选择2001/2005收治的20例自体外周血造血干细胞移植患者,男11例,女9例,其中急性髓细胞白血病11例,急性淋巴细胞白血病5例,恶性淋巴瘤3例,多发性骨髓瘤1例。根据患者对药价承受能力分为2组:国产重组人粒细胞集落刺激因子动员组、进口重组人粒细胞集落刺激因子动员组,每组各10例,除急性髓细胞白血病采用大剂量阿糖胞苷动员外,其他均应用大剂量环磷酰胺动员,当白细胞降至低谷开始回升时加国产与进口重组人粒细胞集落刺激因子,白细胞升至5×109L-1以上开始采集外周血造血干细胞。所有患者均移植成功,两者在给药剂量、用药天数,采集干细胞质量、造血功能重建及药物毒副反应等方面差异均无显著性意义。
To evaluate the effect of domestic recombinant human granulocyte-colony stimulating factor in mobilizing peripheral hematopoietic stem cells, select 20 patients with autologous peripheral blood stem cell transplantation admitted in 2001/2005, including 11 males and 9 females, including 11 acute myeloid leukemia patients, 5 cases of acute lymphoblastic leukemia, 3 cases of malignant lymphoma, 1 case of multiple myeloma. Patients were divided into two groups according to their affordability: domestic mobilized human granulocyte-colony stimulating factor mobilization group and imported mobilized human granulocyte colony-stimulating factor mobilization group, 10 cases in each group. Except for acute myeloid leukemia, high dose of arabinose Cytidine mobilization, the other are used high-dose cyclophosphamide mobilization, when white blood cells dropped to the trough began to rise plus domestic and imported recombinant human granulocyte colony-stimulating factor, white blood cells rose to 5 × 109L-1 above the collection of peripheral blood stem cells . All patients were successfully transplanted. There was no significant difference between the two groups in the dosage, the number of days of application, the quality of stem cells collected, the reconstruction of hematopoietic function and drug side effects.